NCT01733875 is a Phase 1 clinical trial of CC-220 0.03 mg in Healthy, sponsored by Celgene.

Who is sponsoring NCT01733875?

NCT01733875 is sponsored by Celgene.

What drugs are being tested in NCT01733875?

Interventions in NCT01733875: CC-220 0.03 mg, CC-220 0.1 mg, CC-220 0.3 mg, CC-220 1 mg, CC-220 2 mg, Placebo, CC-220, CC-220, CC-220.

Is NCT01733875 still recruiting?

NCT01733875 is currently completed. Last updated 12 November 2019.

Last reviewed 2019-11-12 · How we verify

NCT01733875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Completed Phase 1 Last updated 12 November 2019

What this trial tests

Phase 1 trial testing CC-220 0.03 mg in Healthy in 65 participants. Completed in 9 October 2013.

Timeline

1 November 2012

Primary endpoint
9 October 2013

9 October 2013

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	other
Enrollment	65
Start date	1 November 2012
Primary completion	9 October 2013
Estimated completion	9 October 2013
Sites	1 location across United States

Drugs / interventions tested

CC-220 0.03 mg — full drug profile →
CC-220 0.1 mg — full drug profile →
CC-220 0.3 mg
CC-220 1 mg — full drug profile →
CC-220 2 mg — full drug profile →
Placebo
CC-220 — full drug profile →
CC-220 — full drug profile →
CC-220 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Celgene — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Novel immunomodulatory drugs and neo-substrates.
Gao S, Wang S, Song Y. · · 2020 · cited 64× · PMID 31938543 · DOI 10.1186/s40364-020-0182-y
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH, Ye Y, Wu L, Kosek J, et al · · 2018 · cited 61× · PMID 29945920 · DOI 10.1136/annrheumdis-2017-212916
First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y, Gaudy A, Schafer P, Thomas M, et al · · 2021 · cited 21× · PMID 32969202 · DOI 10.1002/cpdd.869
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
Molecular glue degrader for tumor treatment.
Hu Y, Yan Y, Wang J, Hou J, et al · · 2024 · cited 8× · PMID 39759140 · DOI 10.3389/fonc.2024.1512666

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01733875 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 12 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01733875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing